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ABSTRACT
CONTEXT AND OBJECTIVE: The purpose of screening tests for cancer is to detect it at an early stage in 
order to increase the chances of treatment. However, their unrestrained use may lead to unnecessary 
examinations, overdiagnosis and higher costs. It is thus necessary to evaluate their clinical effects in terms 
of benefits and harm. 
DESIGN AND SETTING: Review of Cochrane systematic reviews, carried out in the Discipline of Evi‑
dence‑Based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo. 
METHODS: Cochrane reviews on the clinical effectiveness of cancer screening procedures were included. 
Study titles and abstracts were independently assessed by two authors. Conflicts were resolved by another 
two authors. Findings were summarized and discussed. 
RESULTS: Seventeen reviews were selected: fifteen on screening for specific cancers (bladder, breast, 
colorectal, hepatic, lung, nasopharyngeal, esophageal, oral, prostate, testicular and uterine) and two others 
on cancer in general. The quality of evidence of the findings varied among the reviews. Only two reviews 
resulted in high‑quality evidence: screening using low‑dose computed tomography scans for high‑risk 
individuals seems to reduce lung cancer mortality; and screening using flexible sigmoidoscopy and fecal 
occult blood tests seems to reduce colorectal cancer mortality. 
CONCLUSION:  The evidence found through Cochrane reviews did not support most of the commonly 
used screening tests for cancer. It is recommended that patients should be informed of the possibilities 
of false positives and false negatives before they undergo the tests. Further studies to fully assess the ef‑
fectiveness of cancer screening tests and adverse outcomes are required.
RESUMO
CONTEXTO E OBJETIVO: O objetivo do teste de rastreamento para o câncer é detectá‑lo em um estágio 
inicial, a fim de aumentar as chances de cura. Contudo, seu uso descomedido pode levar a exames desne‑
cessários, sobrediagnóstico e aumento de custos. Portanto, é necessário que se avalie a repercussão clínica 
do rastreamento em termos de benefícios e riscos. 
TIPO DE ESTUDO E LOCAL: Revisão de revisões sistemáticas Cochrane realizada na Disciplina de Medicina 
Baseada em Evidências da Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP). 
MÉTODOS: Foram incluídas revisões sobre efetividade clínica de testes de rastreamento para câncer. Os tí‑
tulos e resumos foram avaliados independentemente por dois autores e divergências foram resolvidas por 
outros dois. Os achados foram resumidos e discutidos. 
RESULTADOS: 17 revisões sistemáticas foram incluídas: 15 sobre rastreamento para cânceres específicos 
(vesical, mamário, colorretal, hepático, pulmonar, nasofaríngeo, esofágico, oral, prostático, testicular, ute‑
rino) e duas para câncer em geral. A qualidade das evidências encontradas pelas revisões variou muito. 
Duas revisões encontraram evidências de alta qualidade: o rastreamento com tomografia em dose baixa 
em pacientes de alto risco parece reduzir a mortalidade por câncer pulmonar; e rastreamento com sigmoi‑
doscopia flexível e pesquisa de sangue oculto nas fezes parece reduzir a mortalidade por câncer colorretal. 
CONCLUSÃO: As evidências de revisões sistemáticas Cochrane não indicam a realização dos testes 
mais usados para rastreamento de câncer. Recomenda‑se que os pacientes sejam informados sobre as 
possibilidades de falsos positivos e de falsos negativos antes de serem submetidos aos testes. Estudos 
adicionais para avaliar melhor a eficácia de testes de rastreamento para o câncer e os eventos adversos 
são necessários.
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INTRODUCTION
Cancer is one of the leading causes of morbidity and mortality 
worldwide and was responsible for 8.8 million deaths in 2015. 
Its incidence is expected to increase by about 70% over the next 
two decades.1 Its vast importance can be perceived from its eco-
nomic impact on public health, which was estimated as US$ 1.16 
trillion in 2010.2 
Screening tests are one of the main pillars of early detection. 
They are performed on healthy individuals presenting different lev-
els of risk, with the aim of detecting the disease at an early stage, 
even before any symptom becomes noticeable. However, carrying 
out these tests within screening-based programs is only justified 
if they lead to better health outcomes than would be achieved by 
treating diseases at a later stage.3 Theoretically, the aim in perform-
ing such tests is to minimize the number of people with the disease 
who pass through them undetected (high sensitivity), while also 
minimizing the number of people without cancer who are selected 
for further examination (high specificity).4
The first concept that needs to be underscored in making a 
decision to implement screening is overdiagnosis. This is epide-
miologically defined as a situation of diagnosing a condition that 
during the patient’s lifetime would have remained indolent if left 
undetected.5 The main consequence from this would be overtreat-
ment, which would have no benefits for the patients, might cause 
harm and possibly would generate costs. Additionally, it could divert 
healthcare professionals and resources away from the most severely 
ill patients.5 One well-known example of overdiagnosis took place 
during the 1950s in the United States, when breast self-examina-
tion (BSE) was widely advocated, only for it to be concluded in the 
1990s that BSE had no impact on reducing breast cancer mortality.6
A second important concept to have in mind is the likelihood 
of false-negative results. Aside from the delay in detection of the 
disease and its further development, such situations could lead to 
legal action from patients affected by them, and more importantly, 
could reduce public confidence in screening policies.7
Another important aspect of screening programs to be taken 
into consideration is that the likelihood that a positive test will give 
a correct result (positive predictive value) is strongly dependent 
on the prevalence of the disease within the population. Hence, the 
effectiveness of screening programs varies between different regions. 
Furthermore, the effectiveness of screening tests is also affected by 
other variables such as adequate infrastructure, resources and profes-
sional qualification.4  For example, although magnetic resonance imag-
ing may have higher efficacy for detection of breast cancer, compared 
with conventional mammography, the infrastructure cost and the high 
number of false-positive results considerably increases its costs and 
harm, thus leading to a preference for conventional mammography.8
Finally, screening strategies should be implemented only in set-
tings in which further investigation and treatment are warranted 
for all individuals, whenever necessary. Otherwise, there is no 
benefit even for evidence-based screening protocols.
OBJECTIVE
The objective of this study was to summarize the evidence from 
Cochrane systematic reviews regarding the clinical effectiveness 
of screening tests for detection of different types of cancer.
METHODS
Design and setting 
This was a review of Cochrane systematic reviews carried out in 
the Discipline of Evidence-Based Medicine, Escola Paulista de 
Medicina — Universidade Federal de São Paulo (EPM-Unifesp). 
This article was specifically developed for the section “Cochrane 
Highlights”, which is an initiative for disseminating Cochrane 
reviews. This initiative resulted from a formal partnership 
between the São Paulo Medical Journal and the Cochrane 
Collaboration, and it is supported by Cochrane Brazil.
Criteria for including reviews 
• Types of studies 
 Only Cochrane systematic reviews on effectiveness and safety, 
including randomized, quasi-randomized or non-randomized 
clinical trials as primary studies, were used in producing the 
present review. Systematic reviews focusing on  diagnostic accu-
racy were excluded. Protocols, withdrawn reviews and previous 
versions of updated reviews were not taken into consideration.
• Types of participants
 All types of participants, regardless of sex and age or other 
characteristics (i.e. different risks for cancer, genetic factors, 
previous cancer), were included. 
• Types of intervention
 Any screening approaches for cancer detection were included. 
• Type of outcomes 
 Clinical outcomes involving morbidity and mortality were 
considered. 
Search for reviews 
We developed and applied a systematic search strategy in the 
Cochrane Library on December 19, 2016 (Table 1). Two researchers 
Table 1. Search strategy in Cochrane Library. December 19, 2016
#1 “Screening” in title, abstract, keywords
#2 “Mass Screening” in title, abstract, keywords
#3 “Early Detection of Cancer” in title, abstract, keywords
#4 “ Screen test” in title, abstract, keywords
#5 “Screen” in title, abstract, keywords
#¨6 #1 OR #2 OR #3 OR #4 OR #5 
#7 #¨6 in Cochrane Reviews
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Table 2. Issues addressed, main findings and quality of evidence from systematic reviews that included at least one randomized clinical trial
Type of  
cancer
Screening  
methods
Population (n)
Design of 
studies 
included
Benefits  
and harm
Quality of 
evidence 
(GRADE 
approach*)
Hepatocellular 
carcinoma
Alpha-fetoprotein 
and/or liver 
ultrasonography 
versus no screening18
Individuals with 
chronic hepatitis B
RCT (3)
There is no evidence to support or  
refute the use of alpha-fetoprotein.
Not assessed
Lung cancer 
More frequent chest 
x-ray screening versus 
less frequent chest 
x-ray screening19
General 
population
RCT (8)
Controlled 
trial (1)
No reduction of lung cancer mortality.
No reduction of all-cause mortality.
Low to 
moderate
Annual chest x-ray 
versus no regular 
screening19
General 
population
No reduction of lung cancer mortality  
after 6 and 13 years of follow-up.
No reduction of all-cause mortality.
High
Annual chest x-ray 
plus four-monthly 
sputum cytological 
tests versus annual 
chest x-ray alone19
General 
population 
Chest x-ray plus sputum cytological tests do not reduce 
lung cancer mortality or all-cause mortality, and do not 
increase lung cancer 5-year survival.
Moderate to 
high
Annual low-dose  
CT versus annual  
chest x-ray19
High-risk 
individuals (aged 
55 to 74 years with 
30 pack-years or 
more of smoking, 
or who quitted 15 
years or less prior 
to enrolment if 
ex-smokers)
Low-dose computed tomography  
seems to reduce lung cancer mortality.
Low-dose computed tomography does  
not seem to reduce all-cause mortality.
High
Colorectal 
cancer
Fecal occult blood 
screening versus no 
screening16 
General 
population 
RCT (4)
Screening seems to reduce colorectal cancer mortality.
It is possible that screening  
reduces colorectal cancer incidence.
Not assessed
Flexible 
sigmoidoscopy  
and fecal occult  
blood test17
General 
population 
RCT (9)
Screening with both flexible sigmoidoscopy  
and fecal occult blood testing seems to  
reduce colorectal cancer mortality.
Screening with flexible sigmoidoscopy  
seems to reduce colorectal cancer incidence.
Screening with fecal occult blood testing does  
not seem to reduce colorectal cancer incidence.
Moderate to 
high
Continue...
(ATPB and VLC) selected and assessed systematic reviews with 
themes that showed a correlation with the goals of this review. A 
third researcher (RR or RLP) resolved any conflicts that arose, when 
necessary.
RESULTS
Search results
The search resulted in 927 Cochrane systematic reviews. 
After the titles and abstracts had been screened, 17 reviews 
were found to be related to the theme and fulfilled our inclu-
sion criteria.9-25 Among these, 7 reviews assessed a screening 
method only for the general population, 7 only for a specific 
subpopulation and 3 for both. The reviews assessed screening 
approaches for the following types of cancer: cancer in gen-
eral (n = 2),  bladder (n = 1), breast (n = 4), colorectal (n = 2), 
hepatic (n = 1), lung (n = 1), nasopharyngeal (n = 1), esopha-
geal (n = 1), oral (n = 1), prostate (n = 1), testicular (n = 1) and 
uterine (n = 1). 
Results from systematic reviews
The 17 systematic reviews are presented below. Additionally, for 
those that included at least one primary study, a brief sum-
mary is then presented. The issues addressed, the main findings 
from each screening approach and the quality of the evidence 
(based on the GRADE approach26) are presented in Table 2.
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Type of  
cancer
Screening  
methods
Population (n)
Design of 
studies 
included
Benefits  
and harm
Quality of 
evidence 
(GRADE 
approach*)
Cancer 
(overall)
General health 
checkup versus no 
checkup9
General 
population 
RCT (16) No reduction of cancer mortality. High 
General tests for 
cancer versus no test10
Individuals with 
unprovoked VTE
RCT (2)
General tests seem to lead to earlier diagnosis  
of cancer at an earlier stage of the disease.
Insufficient evidence about  
cancer-related and VTE-related mortality.
Not assessed
Prostate 
cancer 
PSA testing with or 
without digital rectal 
examination versus 
no screening23
General male 
population
RCT (5)
PSA does not seem to reduce mortality
PSA seems to increase the diagnosing of prostate 
cancer and localized prostate cancer and seems to 
reduce the diagnosing of advanced prostate cancer.
Low to 
moderate
Oral cancer
Visual examination 
versus no 
examination22
Adults > 35 years 
old
RCT (1)
Visual examination does not seem to reduce mortality. Not assessed
High-risk 
individuals, > 35 
years old, who 
used tobacco or 
alcohol or both
Visual examination seems to reduce  
oral cancer mortality, to improve survival  
and to reduce the number of individuals  
diagnosed with oral cancer of stage III or worse.
Not assessed
Breast cancer
Intensive follow-up 
(more intensive 
scheme with 
radiological and 
laboratory tests) 
versus non-intensive 
follow-up (regular 
physical examinations 
and yearly 
mammography 
alone)12
Women treated 
for stage 1, 2 or 3 
breast cancer
RCT (5)
Intensive follow-up seems do  
not increase overall survival.
Intensive follow-up does not seem to  
increase disease-free survival.
Intensive follow-up does not seem 
to increase quality of life.
Low to high
Centralized follow-up 
(by a hospital-based 
specialist) versus 
decentralized 
follow-up (by general 
practitioners)12
Women treated 
for stage 1, 2 or 3 
breast cancer
Centralized follow-up does not  
seem to increase overall survival.
Centralized follow-up does not seem  
to increase disease-free survival.
Centralized follow-up does not  
seem to increase quality of life.
Moderate  
to high
Regular breast 
self-examination 
versus no 
regular breast 
self-examination14
General female 
population
RCT (3)
Regular self-examination does not  
reduce breast cancer mortality.
Regular self-examination doubled the  
number of biopsies with benign results.
Not assessed
Mammography 
screening versus
no mammography 
screening15
Women aged from 
39 to 74 years
RCT (8)
Screening does not seem to reduce breast  
cancer mortality after 10 and 13 years  
(including only good-quality studies)
Screening does not seem to reduce all-cancer mortality 
after 13 and years (including only good-quality studies)
Screening seems to increase the  
numbers of lumpectomies and  
mastectomies and use of radiotherapy.
Screening does not seem to  
change the use of chemotherapy.
Not assessed
Table 2. Continuation.
RCT = randomized controlled trial; *GRADE = Grading of Recommendations Assessment, Development and Evaluation;26 VTE = venous thromboembolism; 
PSA = prostate‑specific antigen.
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General health checkup among adults 
The purpose of general health checkups is to detect disease and risk 
factors for disease with the aim of reducing morbidity and mor-
tality. In this review,9 the authors aimed to quantify the benefits 
and harm of general health checkups with an emphasis on patient-
relevant outcomes such as morbidity and mortality. The  results 
showed that there was no difference between the checkup and 
‘no checkup’ groups regarding cancer-related mortality (risk ratio 
[RR] 1.02; 95% confidence interval [95% CI] 0.92 to 1.12; eight ran-
domized clinical trials [RCTs]; 139,290 participants; 3663 deaths). 
The authors concluded that general health checkups did not reduce 
cancer-related morbidity or mortality, but that the number of new 
diagnoses increased. Important harmful outcomes, such as the 
number of follow-up diagnostic procedures or short term psycho-
logical effects, were often not studied or reported and many trials 
had methodological problems. With the large number of partici-
pants and deaths included and the long follow-up periods used, 
and considering that cancer mortality was not reduced, general 
health checkups are unlikely to be beneficial. For further details, 
refer to the original abstract, available at: http://onlinelibrary.wiley.
com/doi/10.1002/14651858.CD009009.pub2/full.
Tests for cancer in patients with 
unprovoked venous thromboembolism
An unprovoked venous thromboembolism (VTE) is one that 
affects patients with no underlying or immediately predisposing 
risk factors. It can frequently be the first clinical manifestation of 
an underlying malignancy. This raises the question of whether 
patients with an unprovoked VTE should be investigated for an 
underlying cancer. The treatment for VTE differs between cancer 
and non-cancer patients, and a correct diagnosis would ensure 
that patients received optimal treatment for VTE, to prevent 
recurrence and further morbidity. The objectives of this review10 
were to determine whether cancer testing for patients with a first 
episode of unprovoked VTE is effective in reducing cancer and 
VTE-related mortality and morbidity and to establish which tests 
for cancer are most useful. Two RCTs (396 patients) assessed the 
effect of routine cancer tests versus clinically indicated cancer 
tests for patients with an unprovoked VTE. Cancer-related mor-
tality did not differ between the two testing approaches (odds 
ratio [OR] 0.49; 95% CI 0.15 to 1.67; P = 0.26; moderate quality 
evidence). Neither of the studies measured all-cause mortality, 
VTE-related morbidity and mortality, adverse events, or patient 
satisfaction. The authors concluded that there was currently 
insufficient evidence for firm conclusions regarding the effec-
tiveness of cancer testing for a first episode of unprovoked VTE. 
The results were imprecise and could be consistent with either 
harm or benefit. Further good-quality RCTs are needed before 
definitive conclusions can be reached. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD010837.pub2/full.
Follow-up strategies for women treated for early breast cancer 
Follow-up examinations are often used, after primary treatment 
for women with breast cancer, to detect recurrences at an early 
(asymptomatic) stage. The objective of this systematic review12 
was to evaluate the effectiveness of different follow-up strategies 
for detecting distant metastasis, regarding mortality, morbid-
ity and quality of life among women who had been treated for 
stage 1, 2 or 3 breast cancer. This updated review included five 
RCTs involving 4,023 women with breast cancer (clinical stage 
1, 2 or 3). Two trials involving 2,563 women compared follow-
up based on clinical visits and mammography with a more inten-
sive scheme including radiological and laboratory tests. The data 
showed that there were no significant differences between the 
two strategies in relation to the following outcomes:
• Overall survival (hazard ratio [HR] 0.98; 95% CI 0.84 to 1.15; 
two RCTs; 2,563 participants; high-quality evidence);
• Disease-free survival (HR 0.84; 95% CI 0.71 to 1.00; two RCTs; 
2,563 participants; low-quality evidence);
• Quality-of-life measurements (one RCT; 639 participants; 
high-quality evidence).
The results from subgroup analyses according to patient age, 
tumor size and lymph node status before primary treatment were 
consistent. In 1999, 10-year follow-up data became available for 
one RCT, and no significant differences in overall survival were 
found. Two RCTs compared follow-up performed by a hospital-
based specialist versus follow-up performed by general practi-
tioners and showed the following results according to outcome:
• Overall survival: no difference between the strategies (HR 1.07; 
95% CI 0.64 to 1.78; one RCT; 968 participants; moderate-
quality evidence);
• Time elapsed until detection of recurrence: no difference 
between the strategies (HR 1.06; 95% CI 0.76 to 1.47; two stud-
ies; 1,264 participants; moderate-quality evidence);
• Quality of life: no difference between the strategies (one RCT; 
356 participants; high-quality evidence);
• Patient satisfaction: greater among patients treated by general 
practitioners.
One RCT (196 women) compared regularly scheduled follow-
up visits versus less frequent visits restricted to the time of mam-
mography. No significant differences emerged in relation to interim 
use of telephone contacts and frequency of consultations with gen-
eral practitioners. The authors concluded that follow-up programs 
based on regular physical examinations and yearly mammogra-
phy alone are as effective as more intensive approaches based on 
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regularly performing laboratory and instrumental tests, in terms 
of the time that elapsed until detection of recurrence, overall sur-
vival and quality of life. In two RCTs, follow-up care provided by 
trained and untrained general practitioners working in an orga-
nized practice setting had comparable effectiveness to that delivered 
by hospital-based specialists, in terms of overall survival, detec-
tion of recurrence and quality of life. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD001768.pub3/full.
Regular self-examination or clinical  
examination for early detection of breast cancer
The practice of clinical breast examination and breast self-exam-
ination has been widely disseminated and advocated for years 
as a general screening method for diagnosing breast cancer. 
This systematic review14 aimed to assess the clinical effectiveness 
of these practices and found two large population-based studies 
(n = 388,535 women) that had been conducted in Shanghai and 
Russia, comparing breast self-examination with no intervention 
(control group). The results showed:
• There was no statistically significant difference in breast cancer 
mortality between the groups (RR 1.05; 95% CI 0.90 to 1.24; 
587 deaths in total);
• In Russia, more cancers were diagnosed in the self-examina-
tion group than in the control group (RR 1.24; 95% CI 1.09 to 
1.41), whereas in Shanghai there was no statistical difference 
between the groups (RR 0.97; 95% CI 0.88 to 1.06);
• In the screening groups, nearly twice as many biopsies (n = 3,406) 
with benign results were conducted, compared with the control 
group (n = 1,856) (RR 1.88; 95% CI 1.77 to 1.99).
Another large population-based study on combined breast 
self-examination and clinical breast examination was also included, 
but this study was discontinued due to lack of compliance with 
follow-up, and no conclusions were drawn. The authors of the 
systematic review concluded that there was no suggestion of any 
beneficial effect from breast self-examination screening. Rather, 
there was only increased harm due to increased numbers of benign 
lesions identified, with consequently increased numbers of biopsies 
performed. Therefore, screening by means of physical examina-
tion and breast self-examination is no longer recommended. For 
further details, refer to the original abstract, available at: http://
onlinelibrary.wiley.com/doi/10.1002/14651858.CD003373/full.
Screening for breast cancer via mammography
This review15 aimed to assess the benefits and harm of mam-
mographic screening for breast cancer. It included seven 
RCTs (600,000 women, of ages ranging from 39 to 74 years) 
in which results from mammographic screening and without 
mammographic screening were compared. The pooled results 
from three RCTs with good methodological quality showed that 
mammographic screening did not reduce:
• Breast cancer-related mortality after 13 years (RR 0.90; 
95% CI 0.79 to 1.02);
• All cancer-related mortality, including breast cancer, after 
10 years (RR 1.02; 95% CI 0.95 to 1.10);
• All-cause mortality after 13 years (RR 0.99; 95% CI 0.95 to 1.03).
The total numbers of lumpectomies and mastectomies were sig-
nificantly larger (31% higher) in the screened groups (RR 1.31; 95% 
CI 1.22 to 1.42), as were the numbers of mastectomies (20% higher) 
(RR 1.20; 95% CI 1.08 to 1.32). The use of chemotherapy and 
radiotherapy was similarly increased in both groups (screened and 
non-screened). The authors concluded that if the overdiagnosis 
and overtreatment rates were 30%, 10 years of screening on 2000 
women would have the outcomes that one women would avoid 
dying of breast cancer and 10 healthy women would be treated 
unnecessarily. Also, 200 women would experience significant psy-
chological distress (anxiety and uncertainty) due to false-positive 
findings. Furthermore, the authors stated that given the substantial 
advances in treatment and the greater breast cancer awareness that 
had been achieved since the time when these RCTs were under-
taken, it was most likely that the absolute effect of screening at the 
time of writing was smaller than at the time of the trials. They also 
noted that there were recent studies showing greater degrees of 
overdiagnosis and very little or no reduction in the incidence of 
advanced cancers through screening. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD001877.pub5/full.
Screening for colorectal cancer using  
the fecal occult blood test (Hemoccult)
The fecal occult blood test (FOBT) is used as a population-
based screening for reducing mortality due to colorectal can-
cer. This review16 evaluated whether screening using FOBT 
(guaiac  or immunochemical) indeed reduces colorectal cancer 
mortality and what the benefits and harm from screening might 
be. Meta-analyses on four RCTs showed that participants allo-
cated to FOBT screening had a reduction in the risk of colorec-
tal cancer mortality of 16%, compared with no FOBT screening 
(RR 0.84; 95% CI 0.78-0.90). The authors concluded that bene-
fits from the screening included: moderate reduction in mortal-
ity due to colorectal cancer; possible reduction in the incidence 
of cancer through detection and removal of colorectal adenomas; 
and, potentially, the less invasive surgery that earlier treatment 
of colorectal cancers may involve. The harmful effects from the 
screening included: the psychosocial consequences of receiving 
a false-positive result; the potentially significant complications of 
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colonoscopy or a false-negative result; the possibility of overdiag-
nosis (leading to unnecessary investigations or treatment); and 
the complications associated with treatment. For further details, 
refer to the original abstract, available at: http://onlinelibrary.
wiley.com/doi/10.1002/14651858.CD001216.pub2/full.
Flexible sigmoidoscopy versus fecal occult  
blood testing for colorectal cancer screening 
Screening using FOBT and flexible sigmoidoscopy have been 
shown to reduce mortality due to colorectal cancer in randomized 
controlled trials. The objective of this review17 was to compare the 
effectiveness of screening for colorectal cancer using flexible sig-
moidoscopy versus screening using the FOBT. For this purpose, 
a search for RCTs comparing screening using flexible sigmoid-
oscopy or FOBT, with each other or with no screening, was con-
ducted. Only studies reporting mortality due to colorectal cancer 
were included. FOBT had to be repeated (annually or biennially). 
Nine RCTs involving 338,467 individuals randomized to screen-
ing and 405,919 individuals to control groups were identified. 
Five RCTs compared flexible sigmoidoscopy with no screening 
and four studies compared repetitive guaiac-based FOBT (annu-
ally and biennially) with no screening. No studies directly com-
paring the two screening methods were found. Colorectal can-
cer mortality was lower when flexible sigmoidoscopy was used 
(RR 0.72; 95% CI 0.65 to 0.79; high-quality evidence) than  with 
no screening and when FOBT was used (RR 0.86; 95% CI 0.80 
to 0.92; high-quality evidence). Based on indirect comparison 
of the two screening methods, the RR of dying due to colorectal 
cancer was 0.85 (95% CI 0.72 to 1.01; low-quality evidence) for 
screening using flexible sigmoidoscopy, in comparison with FOBT. 
No complications occurred after the FOBT test itself, but 0.03% 
of the participants suffered a major complication after follow-up. 
Among more than 60,000 flexible sigmoidoscopy screening pro-
cedures and almost 6,000 work-up colonoscopies, a major compli-
cation was recorded in 0.08% of the participants. The authors con-
cluded there was high-quality evidence showing that screening by 
means of flexible sigmoidoscopy and FOBT reduced the mortality 
due to colorectal cancer. On the other hand, there was low-qual-
ity indirect evidence that screening using one of the approaches 
reduced colorectal cancer deaths more than the other. Major com-
plications associated with screening require validation from studies 
with more complete reporting of harm. For further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD009259.pub2/full.
Alpha-fetoprotein and/or ultrasonography  
for liver cancer screening in patients with hepatitis B 
This review18 included three RCTs, and each of them used a dif-
ferent method for liver cancer screening. The first one, conducted 
in Shanghai, China, randomized the participants to screen-
ing every six months using alpha-fetoprotein and ultrasonog-
raphy (n = 9,373) versus no screening (n = 9,443). The second 
trial, conducted in Toronto, Canada, on 1,069 participants with 
chronic hepatitis B, compared screening every six months with 
alpha-fetoprotein alone (n = 532) versus alpha-fetoprotein and 
ultrasound (n = 538) over a five-year period. The last study, con-
ducted in Taiwan, was designed as a cluster randomized trial to 
determine the optimal interval for screening using alpha-feto-
protein and ultrasound. Screening intervals of 4 and 12 months 
were compared in the groups. 
The results from the first two studies did not show any signifi-
cant conclusions. The third study only showed increased incidence 
of hepatocellular carcinoma in the four-monthly screening group.
None of the three trials included any reports on adverse events. 
The authors of this systematic review judged that the specificity 
and sensitivity of the trials were poor. 
The results were inconclusive since there was not enough evi-
dence to evaluate the value of alpha-fetoprotein or ultrasound 
screening, or both, for patients with hepatocellular carcinoma who 
were positive for hepatitis B surface antigen (HBsAg). For further 
details, refer to the original abstract, available at: http://onlineli-
brary.wiley.com/doi/10.1002/14651858.CD002799.pub2/full.
Screening for lung cancer
The objective of this review19 was to determine whether screening 
for lung cancer (using sputum examinations, chest radiography 
or chest computed tomography) reduced mortality. Eight RCTs 
and one non-randomized trial (453,965 subjects) were included 
and these showed the following:
• Comparison of annual chest X-ray screening for smokers and 
non-smokers versus no screening: no reduction in lung cancer 
mortality (RR 0.99; 95% CI 0.91 to 1.07; one study); 
• Comparison of different frequencies of chest X-ray screen-
ing: frequent screening was associated with an 11% relative 
increase in mortality due to lung cancer, compared with less 
frequent screening (RR 1.11; 95% CI 1.00 to 123; low-quality 
evidence);
• Comparison of screening using chest X-ray plus sputum cyto-
logical tests versus screening using chest X-ray alone: no reduc-
tion in lung cancer mortality (RR 0.88; 95% CI 0.74 to 1.03); 
• Comparison of annual low-dose computed tomography screen-
ing versus annual chest X-ray screening for high-risk smokers 
and ex-smokers: low-dose computed tomography screening 
was associated with a 20% decrease in mortality due to lung 
cancer (RR 0.80; 95% CI 0.70 to 0.92).
The authors concluded there was no current evidence to sup-
port screening for lung cancer using chest radiography or sputum 
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cytological tests. Annual low-dose computed tomography screen-
ing was correlated with a reduction in lung cancer mortality among 
high-risk smokers. However, it is essential to obtain further data 
on the cost-effectiveness of screening and the relative harm and 
benefits of screening across a range of different groups at risk and 
different settings. For further details, refer to the original abstract, 
available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD001991.pub3/full.
Screening programs in oral cancer 
This review22 aimed to assess the effectiveness of screening 
(using visual examination, toluidine blue, fluorescence imaging 
or brush biopsy) for early detection and prevention of oral can-
cer. Only one RCT, with a 15-year follow-up, met the inclusion 
criteria. This RCT found that there was a 24% reduction in mor-
tality associated with screening (30/100,000 person-years ver-
sus 39/100,000; RR 0.76; 95% CI 0.60 to 0.97) among high-risk 
individuals who used tobacco or alcohol or both. Moreover, the 
screening group presented a 19% reduction in the number 
of individuals diagnosed with oral cancer in stage 3 or higher 
(RR  0.81; 95% CI  0.70 to 0.93). The authors concluded that 
there was evidence that visual examination as part of a popula-
tion-based screening program could reduce oral cancer mortal-
ity among high-risk individuals and that there was a reduction 
in staging and an improvement in survival across the popula-
tion. There was no evidence to support use of adjunctive tech-
nologies (including toluidine blue, brush biopsy or fluorescence 
imaging) as a screening tool to reduce oral cancer mortality. 
However, the evidence was limited to one study that presented 
high risk of bias and which did not consider the effect of clus-
ter randomization in the analysis. For  further details, refer to 
the original abstract, available at: http://onlinelibrary.wiley.com/
doi/10.1002/14651858.CD004150.pub4/full.
Screening for prostate cancer
Routine mass, selective or opportunistic screening for prostate 
cancer has resulted in considerable debate regarding whether this 
screening indeed reduces mortality and improves quality of life. 
The objectives of this systematic review23 were to assess whether 
screening for prostate cancer reduces prostate cancer-specific 
mortality or all-cause mortality and to determine its impact on 
quality of life and adverse events, so as to better inform deci-
sion-making relating both to individual patients and to health-
care policy.
Five RCTs (341,342 participants, aged from 45 to 80 years, 
with duration of follow-up from 7 to 20 years) were included 
and all of them involved prostate-specific antigen testing, with 
or without digital rectal examination. There was no signifi-
cant difference in prostate cancer-specific mortality between 
the screened and non-screened groups (RR 1.00; 95% CI 0.86 
to 1.17). Three RCTs presented high risk of bias, and the other 
two were classified as having low risk of bias, but provided con-
tradictory results, as follows:
• The European Randomized Study of Screening for Prostate 
Cancer (ERSPC) reported that screening led to a significant 
reduction in prostate cancer-specific mortality (RR 0.84; 95% 
CI 0.73 to 0.95). This study was the only RCT that reported a 
significant reduction in prostate cancer-specific mortality in 
a pre-specified subgroup of men aged 55 to 69 years of age.
• The US Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
Screening Trial reported that screening did not lead to any sig-
nificant benefit (RR 1.15; 95% CI 0.86 to 1.54).  
A meta-analysis on these two studies with low risk of bias alone 
(ERSPC and PLCO) showed that there was no significant differ-
ence in prostate cancer-specific mortality (RR 0.96; 95% CI 0.70 to 
1.30). Prostate cancer was diagnosed significantly more frequently 
among screened men than among unscreened men (RR 1.30; 95% 
CI 1.02 to 1.65). Localized prostate cancer was diagnosed more 
frequently among screened men (RR 1.79; 95% CI 1.19 to 2.70), 
and advanced prostate cancer was diagnosed less frequently among 
screened men (RR 0.80; 95% CI 0.73 to 0.87).
Screening led to a variety of harms, including bleeding, bruis-
ing, short-term anxiety, overdiagnosis and overtreatment, infec-
tion, blood loss, requirement of transfusion, pneumonia, erectile 
dysfunction and incontinence. The adverse events related to biop-
sies guided by transrectal ultrasound (TRUS) included infection, 
bleeding and pain. No deaths were directly related to any biopsy 
procedure. None of the RCTs provided any detail about quality 
of life as an outcome. The authors concluded that prostate cancer 
screening did not significantly decrease prostate cancer-specific 
mortality. A single RCT (ERSPC) found a 21% reduction of pros-
tate cancer-specific mortality in a pre-specified subgroup of men 
aged 55 to 69 years. A meta-analysis showed that there was no 
significant reduction in prostate cancer-specific or overall mor-
tality. Harm of moderate severity is frequently associated with 
prostate cancer-specific screening and further diagnostic evalu-
ations. Overdiagnosis and overtreatment occur frequently and 
are associated with treatment-related harm. Individuals need 
to be aware of this when they are deciding whether to undergo 
screening. A reduction in prostate cancer-specific mortality 
may take up to 10 years to accrue and therefore men whose 
life expectancy is less than 10 to 15 years need to be aware that 
screening is unlikely to be beneficial. No studies examined the 
independent role of screening by means of digital rectal exami-
nation. For further details, refer to the original abstract, avail-
able at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD004720.pub3/full.
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Six systematic reviews that did not find any primary study that 
fulfilled their inclusion criteria (empty reviews) were also included 
in our review. Their aims were to evaluate the following:
• Screening using urinary dipsticks for reducing morbidity and 
mortality;11 
• Mammography versus mammography plus ultrasonography 
for breast cancer screening testing in women at average risk;13 
• Screening for nasopharyngeal cancer;20 
• Screening for esophageal cancer;21 
• Screening for testicular cancer;24 
• Follow-up strategies after treatment (large loop excision of the 
transformation zone (LLETZ)) for cervical intraepithelial neo-
plasia (CIN): Impact of human papillomavirus (HPV) test.25 
Thus, no recommendations in relation to the topics of these six 
systematic reviews can be made until primary studies, preferably 
RCTs with strong methodological quality, have been published.
DISCUSSION
The present study included 17 Cochrane systematic reviews: 
15  relating to screening for specific types of cancer and 2 to 
screening for cancer in general. However, 6 of the 17 reviews 
did not find any clinical trial that met the inclusion criteria, and 
therefore the authors of those “empty reviews” were unable to 
provide recommendations on the benefits and risks of screening. 
These last reviews were on screening for bladder, breast, naso-
pharyngeal, esophageal, testicular and cervical cancer.
Many clinical trials included in the systematic reviews were 
small, had short-term follow-up and were of poor methodological 
quality, which limited the quality of evidence available for many 
relevant outcomes. This was notable in relation to the reviews on 
screening among individuals with idiopathic deep venous throm-
bosis,10 screening for hepatocellular carcinoma among individu-
als with chronic hepatitis B18 and screening for oral cancer in the 
general population.22
Regarding the screening strategies most commonly used by 
professionals on populations, a systematic review14 showed that 
routinely performed breast self-examination did not reduce can-
cer mortality and also doubled the number of biopsies with benign 
outcomes.
There continues to be discussion concerning mammography 
for breast cancer screening. On the basis of a Cochrane systematic 
review, mammographic screening does not seem to have benefits 
regarding breast cancer mortality or cancer-related mortality after 
10 and 13 years respectively.15 
For prostate-specific antigen testing with or without digital 
rectal examination for prostate cancer screening, the results from 
the two major RCTs are inconsistent regarding the benefits relat-
ing to mortality.23
Regarding the implications of this study for clinical practice, the 
evidence found here does not support most routinely performed 
screening approaches, given their lack of clinical effectiveness. 
Patients need to be aware of the risks of false-positive and false-
negative results before undergoing screening tests.  
Concerning the implications of this study for further research, 
since only four systematic reviews provided high-quality bod-
ies of evidence, there is a clear need for better designed and bet-
ter conducted clinical trials for assessing the clinical outcomes of 
the various screening methods that are frequently used in clinical 
practice and for assessing the effectiveness of screening for the 
vast majority of cancers. 
CONCLUSION
This overview brought together 17 systematic reviews with dis-
tinct variations in the level of evidence presented, from low to 
high. The evidence found in this overview did not support most 
of the commonly used screening tests for cancer. Therefore, we 
take the view that patients need to be aware of, and well-informed 
about the possibilities of false positives and false negatives before 
undergoing such tests. The number of studies with high-quality 
evidence level pointing towards significantly decreased mortality 
was low. These studies addressed two issues: low-dose computed 
tomography for high-risk individuals, which seemed to reduce 
lung cancer mortality; and flexible sigmoidoscopy and fecal occult 
blood tests, which seemed to reduce colorectal cancer mortality.
Further studies with better quality are needed in order to assess 
the effectiveness of screening tests for cancer as well their side effects. 
REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality 
worldwide: sources, methods and major patterns in GLOBOCAN 2012. 
Int J Cancer. 2015;136(5):E359‑86.
2. Stewart BW, Wild CP. World Cancer Report 2014. Lyon: International 
Agency for Research on Cancer. World Health Organization; 2014. 
Available from: http://publications.iarc.fr/Non‑Series‑Publications/
World‑Cancer‑Reports/World‑Cancer‑Report‑2014. Accessed in 
2017 (Jul 17).
3. Institute for Quality and Efficiency in Health Care (IQWiG). Benefits and 
risks of screening tests.  Available from: https://www.ncbi.nlm.nih.gov/
pubmedhealth/PMH0072602/. Accessed in 2017 (Jul 17).
4. World Health Organization. Screening for various cancers. Geneva: 
World Health Organization; 2016. Available from: http://who.int/cancer/
detection/variouscancer/en/. Accessed in 2017 (Jul 17).
5. Bulliard J‑L, Chiolero A. Screening and overdiagnosis: public health 
implications. Public Health Reviews. 2015;36(1):8.
6. Thornton H, Pillarisetti RR. ‘Breast awareness’ and ‘breast self‑examination’ 
are not the same. What do these terms mean? Why are they confused? 
What can we do? Eur J Cancer. 2008;44(15):2118‑21.
COCHRANE HIGHLIGHTS | Bueno ATP, Capelasso VL, Pacheco RL, Latorraca COC, Castria TB, Pachito DV, Riera R
410     Sao Paulo Med J. 2017; 135(4):401-10
7. Petticrew MP, Sowden AJ, Lister‑Sharp D, Wright K. False‑negative 
results in screening programmes: systematic review of impact and 
implications. Health Technol Assess. 2000;4(5):1‑120. 
8. Peregrino AAF, Vianna CMM, Almeida CEV, et al. Análise de Custo‑
efetividade do rastreamento do câncer de mama com mamografia 
convencional, digital e ressonância [Analysis of Cost‑effectiveness of 
screening for breast cancer with conventional mammography, digital and 
magnetic resonance imaging]. Ciên Saúde Coletiva. 2012;17(1):215‑22.
9. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General 
health checks in adults for reducing morbidity and mortality from 
disease. Cochrane Database Syst Rev. 2012;10:CD009009.
10. Robertson L, Yeoh SE, Stansby G, Agarwal R. Effect of testing for cancer 
on cancer‑ and venous thromboembolism (VTE)‑related mortality and 
morbidity in patients with unprovoked VTE. Cochrane Database Syst 
Rev. 2015;(3):CD010837.
11. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Screening with urinary dipsticks 
for reducing morbidity and mortality. Cochrane Database Syst Rev. 
2015;1:CD010007.
12. Moschetti I, Cinquini M, Lambertini M, Levaggi A, Liberati A. Follow‑up 
strategies for women treated for early breast cancer. Cochrane Database 
Syst Rev. 2016;(5):CD001768.
13. Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination 
with breast ultrasonography versus mammography for breast cancer 
screening in women at average risk. Cochrane Database Syst Rev. 
2013;(4):CD009632.
14. Kösters JP, Gøtzsche PC. Regular self‑examination or clinical examination 
for early detection of breast cancer. Cochrane Database Syst Rev. 
2003;(2):CD003373.
15. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with 
mammography. Cochrane Database Syst Rev. 2013;(6):CD001877.
16. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for 
colorectal cancer using the faecal occult blood test, Hemoccult. 
Cochrane Database Syst Rev. 2007;(1):CD001216.
17. Holme Ø, Bretthauer M, Fretheim A, Odgaard‑Jensen J, Hoff G. Flexible 
sigmoidoscopy versus faecal occult blood testing for colorectal cancer 
screening in asymptomatic individuals. Cochrane Database Syst Rev. 
2013;(9):CD009259.
18. Aghoram R, Cai P, Dickinson JA. Alpha‑foetoprotein and/or liver 
ultrasonography for screening of hepatocellular carcinoma in patients 
with chronic hepatitis B. Cochrane Database Syst Rev. 2012;(9):CD:002799.
19. Manser R, Lethaby A, Irving LB, et al. Screening for lung cancer. Cochrane 
Database Syst Rev. 2013;(6):CD001991.
20. Yang S, Wu S, Zhou J, Chen XY. Screening for nasopharyngeal cancer. 
Cochrane Database Syst Rev. 2015;(11):CD008423.
21. Yang S, Wu S, Huang Y, et al. Screening for oesophageal cancer. Cochrane 
Database Syst Rev. 2012;12:CD007883.
22. Brocklehurst P, Kujan O, O’Malley LA, et al. Screening programmes for 
the early detection and prevention of oral cancer. Cochrane Database 
Syst Rev. 2013;(11):CD004150.
23. Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate 
cancer. Cochrane Database Syst Rev. 2013;(1):CD004720.
24. Ilic D, Misso ML. Screening for testicular cancer. Cochrane Database 
Syst Rev. 2011;(2):CD007853.
25. van der Heijden E, Lopes AD, Bryant A, Bekkers R, Galaal K. Follow‑up 
strategies after treatment (large loop excision of the transformation 
zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact 
of human papillomavirus (HPV) test. Cochrane Database Syst Rev. 
2015;1:CD010757.
26. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength 
of recommendations. BMJ. 2004;328(7454):1490.
Sources of funding: None declared
Conflict of interest: None declared
Date of first submission: June 2, 2017
Last received: July 11, 2017
Accepted: July 11, 2017
Address for correspondence:  
Vladimir Lisboa Capelasso 
Evidence‑Based Health Program, Escola Paulista de Medicina — 
Universidade Federal de São Paulo (EPM‑Unifesp)   
Rua Botucatu, 740 – 3o andar  
Vila Clementino — São Paulo (SP)  
CEP 04023‑900 
E‑mail: vladimircapelasso@hotmail.com
